Several presentations will highlight broad
potential of CD19-targeted ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) as a single agent and in combination for the
treatment of non-Hodgkin lymphomas
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs) for patients with hematologic malignancies and solid tumors,
today announced abstracts for ZYNLONTA® and ADCT-602 have been
accepted for presentations at the 63rd American Society of
Hematology (ASH) Annual Meeting, which will be held virtually and
in Atlanta, Georgia from December 11-14, 2021.
“We look forward to sharing data on our targeted ADCs as single
agents and in innovative combinations at the 2021 ASH Annual
Meeting,” said Joseph Camardo, MD, Chief Medical Officer of ADC
Therapeutics. “This will include presentations from investigators
on subset data from our pivotal Phase 2 study and data on the use
of ZYNLONTA post-CAR-T. We are also encouraged by the anti-tumor
activity and manageable safety profile of ZYNLONTA in combination
with ibrutinib. The Phase 2 protocol has recently been amended with
a higher and more frequent dose of ZYNLONTA to potentially enhance
the response and to investigate this combination in earlier lines
of therapy.”
Details of ADC Therapeutics’ oral presentation are as
follows:
Planned Interim Analysis of a Phase 2 Study of Loncastuximab
Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large
B-Cell Lymphoma (LOTIS-3) Abstract: 54 Date and Time: Saturday,
December 11, 2021, 10:45 a.m. EST Session: 627. Aggressive
Lymphomas: Clinical and Epidemiological: Population data for
Aggressive NHL Management Presenter: Carmelo Carlo-Stella, MD,
Department of Biomedical Sciences, Humanitas University, and
Department of Oncology and Hematology, IRCCS Humanitas Research
Hospital, Milan, Italy
Details of ADC Therapeutics’ poster presentations are as
follows*:
Clinical Characteristics and Responses of Patients with
Relapsed or Refractory High-Grade B-cell Lymphoma Treated with
Loncastuximab Tesirine in the LOTIS-2 Clinical Trial Abstract:
3575 Date: Monday, December 13, 2021 Session: 626. Aggressive
Lymphomas: Prospective Therapeutic Trials: Poster III Presenter:
Juan Pablo Alderuccio, MD, Sylvester Comprehensive Cancer Center,
University of Miami, Miami, FL, USA
Combination of Loncastuximab Tesirine and Polatuzumab Vedotin
Shows Increased Anti-Tumor Activity in Pre-Clinical Models of
Non-Hodgkin Lymphoma Abstract: 2273 Date: Sunday, December 12,
2021 Session: 605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster II Presenter: Francesca Zammarchi, PhD,
ADC Therapeutics
CD19-mediated DNA Damage Boost in Lymphoma Cells Treated with
Loncastuximab Tesirine in Combination with PARP inhibitors
Abstract: 1342 Date: Saturday, December 11, 2021 Session: 622.
Lymphomas: Translational—Non-Genetic: Poster I Presenter: Stefania
Fusani, PhD, Oncohematology Division, IEO Istituto Europeo di
Oncologia IRCCS, Milano, Italy
Details of an independently developed ZYNLONTA poster are as
follows:
The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine
Achieved Responses in Patients with Diffuse Large B-cell Lymphoma
Who Relapsed After Anti-CD19 CAR T-Cell Therapy Abstract: 2489
Date: Sunday, December 12, 2021 Session: 626. Aggressive Lymphomas:
Prospective Therapeutic Trials: Poster II Presenter: Paolo F.
Caimi, MD, Cleveland Clinic/Case Comprehensive Cancer Center,
Cleveland, OH, USA
Details of an independently developed ADCT-602 poster are as
follows:
A Phase 1 Trial of ADCT-602, a CD22 Targeting Antibody Drug
Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or
Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia Abstract:
1237 Date: Saturday, December 11, 2021 Session: 614. Acute
Lymphoblastic Leukemias: Therapies, Excluding Transplantation and
Cellular Immunotherapies: Poster I Presenter: Nitin Jain, MD, The
University of Texas MD Anderson Cancer Center, Houston, TX, USA
*Posters will be available in the poster exhibit hall in the
Georgia World Congress Center on these dates: December 11: 9:00
a.m.–7:30 p.m. EST; December 12 & 13: 9:00 a.m.–8:00 p.m. EST.
Presenters planning to attend in-person are expected to present
during the final two hours of the noted viewing time.
The abstracts are available through the ASH
online meeting program and will be published in the November
supplemental issue of Blood.
About ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once
bound to a CD19-expressing cell, ZYNLONTA is internalized by the
cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
The potent payload binds to DNA minor groove with little
distortion, remaining less visible to DNA repair mechanisms. This
ultimately results in cell cycle arrest and tumor cell death.
The U.S. Food and Drug Administration (FDA) has approved
ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult
patients with relapsed or refractory (r/r) large B-cell lymphoma
after two or more lines of systemic therapy, including diffuse
large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL
arising from low-grade lymphoma and also high-grade B-cell
lymphoma. The trial included a broad spectrum of heavily
pre-treated patients (median three prior lines of therapy) with
difficult-to-treat disease, including patients who did not respond
to first-line therapy, patients refractory to all prior lines of
therapy, patients with double/triple hit genetics and patients who
had stem cell transplant and CAR-T therapy prior to their treatment
with ZYNLONTA. This indication is approved by the FDA under
accelerated approval based on overall response rate and continued
approval for this indication may be contingent upon verification
and description of clinical benefit in a confirmatory trial.
ZYNLONTA is also being evaluated as a therapeutic option in
combination studies in other B-cell malignancies and earlier lines
of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large B-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211104005798/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com Tel.: +44 7879 627205 Amanda
Hamilton ADC Therapeutics amanda.hamilton@adctherapeutics.com Tel.:
+1 917 288 7023 EU Media Alexandre Müller Dynamics Group
amu@dynamicsgroup.ch Tel: +41 (0) 43 268 3231 USA Media Mary
Ann Ondish ADC Therapeutics maryann.ondish@adctherapeutics.com
Tel.: +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Sep 2023 to Sep 2024